| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L G Mellbin, A Wang, L Rydé. Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. vol 44. issue 3. 2019-10-04. PMID:30805659. |
several sglt-2 inhibitors and glp-1 receptor agonists are associated with a reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke). |
2019-10-04 |
2023-08-13 |
Not clear |
| Han Weina, Niu Yuhu, Holscher Christian, Li Birong, Shen Feiyu, Wang L. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain research. vol 1694. 2019-07-11. PMID:29705602. |
previous research has demonstrated that glp-1 analogs are neuroprotective in several neurological disease models including alzheimer's disease (ad), parkinson's disease (pd), and stroke. |
2019-07-11 |
2023-08-13 |
mouse |
| Vladimer Darsalia, Martin Larsson, Thomas Klein, Cesare Patron. The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors. Cardiovascular diabetology. vol 17. issue 1. 2019-01-28. PMID:29466979. |
the high need for trials assessing functional outcome after stroke rather than stroke prevention with glp-1 agonists and dpp-4 inhibitors. |
2019-01-28 |
2023-08-13 |
Not clear |
| Yanxia Chen, Xiangjian Zhang, Junna He, Yanzhao Xie, Yang Yan. Delayed Administration of the Glucagon-Like Peptide 1 Analog Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. vol 27. issue 5. 2018-08-27. PMID:29395648. |
here, we explored whether delayed administration of a glp-1 analog, liraglutide, could improve long-term functional recovery and promote angiogenesis after stroke. |
2018-08-27 |
2023-08-13 |
mouse |
| Olaf Eberhardt, Helge Topk. Neurological outcomes of antidiabetic therapy: What the neurologist should know. Clinical neurology and neurosurgery. vol 158. 2018-04-02. PMID:28477558. |
recently, semaglutide, a glp-1 analog, has been shown to significantly reduce stroke incidence in a randomized controlled trial. |
2018-04-02 |
2023-08-13 |
Not clear |
| Xavier Rossello, Derek M Yello. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality? International journal of cardiology. vol 228. 2017-11-17. PMID:27865185. |
liraglutide, a glp-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. |
2017-11-17 |
2023-08-13 |
Not clear |
| Yazhou Li, Kou-Jen Wu, Seong-Jin Yu, Ian A Tamargo, Yun Wang, Nigel H Grei. Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke. Experimental neurology. vol 288. 2017-05-12. PMID:27856285. |
proglucagon-derived peptides, especially glucagon-like peptide-1 (glp-1) and its long-acting mimetics, have exhibited neuroprotective effects in animal models of stroke. |
2017-05-12 |
2023-08-13 |
human |
| Angelo Avogaro, Gian Paolo Fadini, Giorgio Sesti, Enzo Bonora, Stefano Del Prat. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovascular diabetology. vol 15. issue 1. 2017-02-09. PMID:27514514. |
after general disappointment around cvots assessing safety of dpp-4 inhibitors (savor, tecos, examine) and the glp-1 receptor agonist lixisenatide (elixa), the empa-reg outcome trial and the leader trial have shown superiority of the sglt2-i empagliflozin and the glp-1ra liraglutide, respectively, on the 3-point mace outcome (cardiovascular death, non-fatal myocardial infarction or stroke) and cardiovascular, as well as all-cause mortality. |
2017-02-09 |
2023-08-13 |
Not clear |
| Huinan Zhang, Yunhan Liu, Shaoyu Guan, Di Qu, Ling Wang, Xinshang Wang, Xubo Li, Shimeng Zhou, Ying Zhou, Ning Wang, Jingru Meng, Xue M. An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke. PloS one. vol 11. issue 2. 2016-07-19. PMID:26863436. |
an orally active allosteric glp-1 receptor agonist is neuroprotective in cellular and rodent models of stroke. |
2016-07-19 |
2023-08-13 |
mouse |
| Libo Zhao, Jia Xu, Qian Wang, Zhonglian Qian, Wanyu Feng, Xiaoxing Yin, Yi Fan. Protective effect of rhGLP-1 (7-36) on brain ischemia/reperfusion damage in diabetic rats. Brain research. vol 1602. 2015-12-14. PMID:25601009. |
it has been reported that stimulating the glp-1 receptor can protect neurons against metabolic and oxidative insults, and therefore can be used in the treatment of stroke and parkinson׳s disease. |
2015-12-14 |
2023-08-13 |
rat |
| Ali Asmar, Lene Simonsen, Meena Asmar, Sten Madsbad, Jens J Holst, Erik Frandsen, Cedric Moro, Thomas Jonassen, Jens Bülo. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American journal of physiology. Endocrinology and metabolism. vol 308. issue 8. 2015-06-19. PMID:25670826. |
in humans, an acute intravenous administration of glp-1 leads to increased cardiac output due to a simultaneous increase in stroke volume and heart rate, whereas no effect on renal hemodynamics could be demonstrated despite significant extraction of both the intact hormone and its primary metabolite. |
2015-06-19 |
2023-08-13 |
human |
| Vladimer Darsalia, Martin Larsson, David Nathanson, Thomas Klein, Thomas Nyström, Cesare Patron. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 35. issue 5. 2015-06-11. PMID:25669907. |
the activation of the glucagon-like peptide 1 receptor (glp-1) for reducing stroke damage is a relatively novel concept that has shown neuroprotective effects in animal models. |
2015-06-11 |
2023-08-13 |
Not clear |
| Michael Gejl, Jørgen Rungby, Birgitte Brock, Albert Gjedd. At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose. Basic & clinical pharmacology & toxicology. vol 115. issue 2. 2015-03-30. PMID:24684709. |
glp-1 interacts with peripheral functions in which the autonomic nervous system plays an important role, and emerging pre-clinical findings indicate a potential neuroprotective role of the peptide, for example in models of stroke and in neurodegenerative disorders. |
2015-03-30 |
2023-08-12 |
Not clear |
| Michael Gejl, Jørgen Rungby, Birgitte Brock, Albert Gjedd. At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose. Basic & clinical pharmacology & toxicology. vol 115. issue 2. 2015-03-30. PMID:24684709. |
this minireview examines the potential of glp-1 as a molecule of interest for the understanding of brain energy metabolism and with reference to the impact on brain metabolism related to appetite and satiety regulation, stroke and neurodegenerative disorders. |
2015-03-30 |
2023-08-12 |
Not clear |
| Vladimer Darsalia, Anna Olverling, Martin Larsson, Shiva Mansouri, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm, Cesare Patron. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regulatory peptides. vol 190-191. 2015-03-30. PMID:24821550. |
however, our results show that linagliptin evokes a differential response on nsc proliferation after stroke in normal and t2d mice suggesting that dpp-4 inhibition effect in the cns might go beyond the well known increase of glp-1. |
2015-03-30 |
2023-08-13 |
mouse |
| Nigel H Greig, David Tweedie, Lital Rachmany, Yazhou Li, Vardit Rubovitch, Shaul Schreiber, Yung-Hsiao Chiang, Barry J Hoffer, Jonathan Miller, Debomoy K Lahiri, Kumar Sambamurti, Robert E Becker, Chaim G Pic. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 10. issue 1 Suppl. 2014-10-06. PMID:24529527. |
prior studies of glucagon-like peptide-1 (glp-1) and long-acting glp-1 receptor agonists have demonstrated neurotrophic/neuroprotective activities across a broad spectrum of cellular and animal models of chronic neurodegenerative (alzheimer's and parkinson's diseases) and acute cerebrovascular (stroke) disorders. |
2014-10-06 |
2023-08-12 |
Not clear |
| Kenichiro Sato, Masahiro Kameda, Takao Yasuhara, Takashi Agari, Tanefumi Baba, Feifei Wang, Aiko Shinko, Takaaki Wakamori, Atsuhiko Toyoshima, Hayato Takeuchi, Tatsuya Sasaki, Susumu Sasada, Akihiko Kondo, Cesario V Borlongan, Mitsunori Matsumae, Isao Dat. Neuroprotective effects of liraglutide for stroke model of rats. International journal of molecular sciences. vol 14. issue 11. 2014-06-03. PMID:24177570. |
in this study, we explored whether liraglutide, a glp-1 analogue exerts therapeutic effects on a rat stroke model. |
2014-06-03 |
2023-08-12 |
rat |
| Christian Hölsche. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. The Journal of endocrinology. vol 221. issue 1. 2014-05-12. PMID:23999914. |
in preclinical studies of alzheimer's disease (ad), parkinson's disease (pd), stroke and other neurodegenerative disorders, it has been shown that most glp-1 mimetics cross the blood-brain barrier and show impressive neuroprotective effects in numerous studies. |
2014-05-12 |
2023-08-12 |
Not clear |
| Christian Hölsche. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS drugs. vol 26. issue 10. 2013-02-14. PMID:22938097. |
in pre-clinical studies, glp-1 and longer-lasting protease-resistant analogues cross the blood-brain barrier, protect memory formation (ad) or motor activity (pd), protect synapses and synaptic functions, enhance neurogenesis, reduce apoptosis, protect neurons from oxidative stress, and reduce plaque formation and the chronic inflammation response in the brains of mouse models of ad, pd, amyotrophic lateral sclerosis, stroke and other degenerative diseases. |
2013-02-14 |
2023-08-12 |
mouse |
| Michael Gejl, Lærke Egefjord, Susanne Lerche, Kim Vang, Bo Martin Bibby, Jens Juul Holst, Annette Mengel, Niels Møller, Jørgen Rungby, Birgitte Brock, Albert Gjedd. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 32. issue 12. 2013-02-01. PMID:22929437. |
reports indicate that glucagon-like peptide-1 (glp-1) may be neuroprotective in models of ad and stroke: although the mechanism is unclear, glucose homeostasis appears to be important. |
2013-02-01 |
2023-08-12 |
Not clear |